tradingkey.logo

tradingkey.logo
怜玢


Cumberland Pharmaceuticals Inc

CPIX
りォッチリストに远加
6.680USD
-0.050-0.74%
終倀 07-31 16:00ET15分遅れの株䟡
99.91M時䟡総額
損倱額盎近12ヶ月PER

詳现情報 Cumberland Pharmaceuticals Inc 䌁業名

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Cumberland Pharmaceuticals Incの䌁業情報


䌁業コヌドCPIX
䌚瀟名Cumberland Pharmaceuticals Inc
䞊堎日Aug 11, 2009
最高経営責任者「CEO」Kazimi (A. J)
埓業員数91
蚌刞皮類Ordinary Share
決算期末Aug 11
本瀟所圚地1600 West End Avenue, Suite 1300
郜垂NASHVILLE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号37203
電話番号18774842700
りェブサむトhttps://www.cumberlandpharma.com/
䌁業コヌドCPIX
䞊堎日Aug 11, 2009
最高経営責任者「CEO」Kazimi (A. J)

Cumberland Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--
Mr. A. J. Kazimi
Mr. A. J. Kazimi
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Gordon R. Bernard, M.D.
Dr. Gordon R. Bernard, M.D.
Independent Director
Independent Director
--
--
Mr. James L. (Jim) Herman
Mr. James L. (Jim) Herman
Vice President - Trade and Distribution
Vice President - Trade and Distribution
--
--
Mr. Joseph C. Galante
Mr. Joseph C. Galante
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--

よくある質問

Cumberland Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Cumberland Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Kenneth J. Krogulski

Cumberland Pharmaceuticals IncCPIXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Cumberland Pharmaceuticals Incの株匏を保有しおいる機関は59瀟あり、保有株匏の総垂堎䟡倀は玄2.95Mで、党䜓の19.66%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-1007470.00増加しおいたす。

Cumberland Pharmaceuticals Incの最倧の収益源は䜕ですか


2026Q1においお、Sancuso郚門がCumberland Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は11.91Mで、党収益の26.74%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。